JP2017536098A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536098A5
JP2017536098A5 JP2017519632A JP2017519632A JP2017536098A5 JP 2017536098 A5 JP2017536098 A5 JP 2017536098A5 JP 2017519632 A JP2017519632 A JP 2017519632A JP 2017519632 A JP2017519632 A JP 2017519632A JP 2017536098 A5 JP2017536098 A5 JP 2017536098A5
Authority
JP
Japan
Prior art keywords
peptide
amino acid
helix
substitution
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017519632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/055156 external-priority patent/WO2016060996A2/en
Publication of JP2017536098A publication Critical patent/JP2017536098A/ja
Publication of JP2017536098A5 publication Critical patent/JP2017536098A5/ja
Pending legal-status Critical Current

Links

JP2017519632A 2014-10-14 2015-10-12 インターロイキン−15組成物及びその使用 Pending JP2017536098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462063784P 2014-10-14 2014-10-14
US62/063,784 2014-10-14
PCT/US2015/055156 WO2016060996A2 (en) 2014-10-14 2015-10-12 Interleukin-15 compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2017536098A JP2017536098A (ja) 2017-12-07
JP2017536098A5 true JP2017536098A5 (enExample) 2018-11-22

Family

ID=55747540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519632A Pending JP2017536098A (ja) 2014-10-14 2015-10-12 インターロイキン−15組成物及びその使用

Country Status (10)

Country Link
US (1) US10350270B2 (enExample)
EP (1) EP3206713A4 (enExample)
JP (1) JP2017536098A (enExample)
KR (1) KR20170068553A (enExample)
CN (1) CN107001438A (enExample)
AU (1) AU2015333827A1 (enExample)
CA (1) CA2963989A1 (enExample)
MX (1) MX2017004838A (enExample)
WO (1) WO2016060996A2 (enExample)
ZA (1) ZA201702213B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018007304A (es) * 2015-12-21 2019-03-14 Armo Biosciences Inc Composiciones de interleucina-15 y sus usos.
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
KR102562519B1 (ko) 2016-10-14 2023-08-02 젠코어 인코포레이티드 IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN119700941A (zh) 2017-05-15 2025-03-28 尼克塔治疗公司 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
EP3645122A1 (en) 2017-06-30 2020-05-06 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
US11524033B2 (en) 2017-09-05 2022-12-13 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
WO2019204646A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
KR20210003170A (ko) 2018-04-18 2021-01-11 젠코어 인코포레이티드 IL-15/IL-15Rα 이종이량체 Fc 융합 단백질 및 이의 용도
JP7479383B2 (ja) 2018-09-27 2024-05-08 エクシリオ デベロップメント, インコーポレイテッド マスクされたサイトカインポリペプチド
PE20211055A1 (es) 2018-10-12 2021-06-07 Xencor Inc Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas
MX2021005485A (es) * 2018-11-09 2021-06-18 Nektar Therapeutics Agonista del receptor de interleuquina-15 de accion prolongada con otro agente farmacologicamente activo.
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
MX2021014189A (es) 2019-05-20 2022-01-06 Cytune Pharma Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas.
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
KR20230096047A (ko) 2020-10-26 2023-06-29 싸이튠 파마 비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제
AU2021367887A1 (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
US12280120B2 (en) 2020-11-25 2025-04-22 Xilio Development, Inc. Tumor-specific cleavable linkers
WO2022268991A1 (en) 2021-06-23 2022-12-29 Cytune Pharma Interleukin 15 variants
WO2023017191A1 (en) 2021-08-13 2023-02-16 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
WO2023086772A1 (en) 2021-11-12 2023-05-19 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
WO2025085672A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63152393A (ja) 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
KR100207766B1 (ko) 1991-01-16 1999-07-15 둘락 노먼 씨. 신생물 질환 치료용 인터루킨-10 조성물
ZA92304B (en) 1991-01-16 1992-09-30 Schering Corp Use of interleukin-10 in adoptive immunotherapy of cancer
US5624823A (en) 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0681589A1 (en) 1993-02-01 1995-11-15 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5552303A (en) * 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
US5665345A (en) 1993-05-24 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting viral replication using IL-10
HUT73463A (en) 1993-07-26 1996-08-28 Schering Corp Agonists and antagonists of human interleukin-10
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
FI962813A0 (fi) 1994-01-20 1996-07-11 Schering Corp IL-10:n käyttö perifeerisen veren yksitumaisten solujen sytolyyttisen aktiivisuuden stimuloimiseen
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5866134A (en) 1995-03-24 1999-02-02 Schering Corporation Method for enhancing the antibody response to specific antigens with Interleukin-10
US5770190A (en) 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
JP2001502521A (ja) * 1996-04-26 2001-02-27 ベス イスラエル デアコネス メディカル センター インターロイキン―15の拮抗剤
US5945097A (en) 1996-09-06 1999-08-31 Schering Corporation Method for lowering cholesterol levels with interleukin-10
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
AU5827000A (en) 1999-07-16 2001-02-05 Maria Teresa Bejarano Viral il-10 uses
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US20030186386A1 (en) 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
AU2001231532A1 (en) 2000-02-11 2001-08-20 Maxygen Aps Improved interleukin 10
EP2295450B1 (en) 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegylated interleukin-10
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
ES2343518T3 (es) 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Polipeptidos interferon alfa modificados resistentes a proteasas.
AU2003280315A1 (en) 2002-11-14 2004-06-03 Maxygen, Inc. Conjugates of interleukin-10 and polymers
ES2312820T3 (es) 2002-11-29 2009-03-01 Maria Grazia Roncarolo Paramicina e il-10 para el tratamiento de enfermedades autoinmunes.
WO2004056850A2 (en) 2002-12-19 2004-07-08 Vib Vzw Mutant proteins showing increased secretion
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
KR101162908B1 (ko) 2002-12-26 2012-07-06 마운틴 뷰 파마슈티컬즈, 인크. 수용체-결합 활성이 보존된, 사이토카인, 케모카인,성장인자, 폴리펩티드 호르몬 및 이들의 길항제의 중합체접합체
AU2004217894B2 (en) 2003-03-03 2010-07-15 Bracco International B.V. Peptides that specifically bind HGF receptor (cMet) and uses thereof
EP1613274B1 (en) 2003-04-15 2010-03-03 GlaxoSmithKline LLC Human il-18 substitution mutants and their conjugates
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
WO2005052159A1 (en) 2003-11-28 2005-06-09 The University Of Sydney Latent phase viral interleukin-10-(vii-10) and uses thereof
EP1718670B1 (en) * 2004-02-27 2011-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity
EP1725589A1 (en) 2004-03-11 2006-11-29 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
AR050693A1 (es) * 2004-08-11 2006-11-15 Zheng Xin Xiao Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.
US20060046961A1 (en) 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CN100334112C (zh) 2004-10-15 2007-08-29 上海海欣生物技术有限公司 人白细胞介素15与Fc融合蛋白
GB0500643D0 (en) 2005-01-13 2005-02-23 Renovo Ltd Medicaments
UY29460A1 (es) 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
EP1901769A2 (en) 2005-05-02 2008-03-26 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
DE602006011311D1 (de) 2005-05-31 2010-02-04 Univ Colorado Il-10 mutante
EP1910513B1 (en) 2005-07-01 2016-08-10 John Schrader Methods of isolating antibody secreting cells from blood samples of immunized animals and generating monoclonal antibodies from said antibody secreting cells.
DK1931704T3 (da) 2005-10-04 2011-03-14 Zymogenetics L L C Frembringelse og rensning af IL-29
WO2007061657A2 (en) 2005-11-14 2007-05-31 The Brigham & Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
US7868139B2 (en) 2006-01-24 2011-01-11 Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
US20080081031A1 (en) 2006-09-28 2008-04-03 Schering Corporation Use of Pegylated IL-10 to Treat Cancer
WO2008041953A2 (en) 2006-10-05 2008-04-10 Agency For Science, Technology And Research Dengue diagnosis and treatment
JP5220025B2 (ja) 2006-12-04 2013-06-26 プロメディオール, インコーポレイテッド 線維症疾患を処置するための併用療法
KR101775929B1 (ko) 2007-01-19 2017-09-07 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
DK2388266T3 (da) * 2007-05-11 2014-05-26 Altor Bioscience Corp Fusionsmolekyler og IL-15-varianter
DE08786222T1 (de) 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
WO2009036568A1 (en) 2007-09-19 2009-03-26 University Health Network Methods and compositions for treating tumors and viral infections
WO2009052454A2 (en) 2007-10-19 2009-04-23 University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
MX2010012579A (es) 2008-05-29 2010-12-20 Squibb Bristol Myers Co Metodos para predecir respuesta de pacientes a modulacion de la via co-estimuladora.
WO2010022227A1 (en) 2008-08-20 2010-02-25 Schering Corporation Methods for monitoring il-10 therapy
EP2379115B1 (en) 2008-12-17 2017-10-25 Merck Sharp & Dohme Corp. Mono- and di-peg il-10 production; and uses
GB2488077A (en) 2009-10-30 2012-08-15 Novozymes Biopharma Dk As Albumin variants
WO2011159878A1 (en) 2010-06-16 2011-12-22 Abbott Laboratories Comparison of protein samples
TR201809437T4 (tr) 2010-07-09 2018-07-23 Affibody Ab Polipeptitler.
US9084761B2 (en) * 2010-07-09 2015-07-21 The Regents Of The University Of California Use of interleukin-15 to treat cardiovascular diseases
WO2012050923A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
CN103547590B (zh) 2010-09-28 2017-11-28 埃格里昂制药股份有限公司 高度可溶性瘦蛋白
CN102145178B (zh) 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
RU2618864C2 (ru) * 2011-09-29 2017-05-11 Энститю Насьональ Де Ля Сантэ Э Дэ Ля Решерш Медикаль (Инсерм) ЛЕНТИВИРУСНЫЕ ВЕКТОРЫ, ПСЕВДОТИПИРОВАННЫЕ МУТАНТНЫМИ BaEV ГЛИКОПРОТЕИНАМИ
JP2015506373A (ja) 2012-01-26 2015-03-02 アムジエン・インコーポレーテツド 成長分化因子15(gdf−15)ポリペプチド
HK1205746A1 (en) 2012-02-29 2015-12-24 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
CN106913865A (zh) 2013-04-18 2017-07-04 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère

Similar Documents

Publication Publication Date Title
JP2017536098A5 (enExample)
JP2011501951A5 (enExample)
ES2871146T3 (es) Molécula de polipéptido con especificidad dual mejorada
IL275497B (en) Serum proteins with type iii fibronectin binding domains
CN102625811B (zh) Fgf21突变体及其用途
JP2019516665A5 (enExample)
EA017690B1 (ru) Мутанты fgf21 и их применение
JP2010534486A5 (enExample)
US20160199479A1 (en) T cell receptors
JP2015212284A5 (enExample)
JP2015518479A5 (enExample)
PE20212075A1 (es) PROTEINAS DE FUSION Fc IL-22 Y METODOS DE USO
JP2012532601A5 (enExample)
JP2015525217A5 (enExample)
EP4190906B1 (en) Engineered polypeptides derived from adenoviral fibre protein and vlps containing the polypeptides
JP2019512222A5 (enExample)
JP2012522529A5 (enExample)
JP2012504965A5 (enExample)
IL269687B (en) Interleukin-2 polypeptides
JP2015511637A5 (enExample)
JP2019530441A5 (enExample)
CN104854127A (zh) 白蛋白结合多肽
CN104045715B (zh) 二聚体化融合蛋白的制备及应用
WO2012164372A1 (en) Recombinant anti-canine parvovirus antibody and uses thereof
TW202304971A (zh) 結合cd71之纖連蛋白iii型結構域